novacap

becomes

Novacap and all its activities unify their names to SEQENS

Novacap and all its activities unified under one new name and become SEQENS. SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering outstanding performance, unrivalled market responsiveness and tailor-made solutions to our customers.

gif
scroll
continuum of progress

Key facts about Seqens

Historical track records

  • Created in 2003 from assets more than a hundred year old
  • 25 years’ experience in CDMO
  • Many successful organic projects achieved: new units and capabilities expansion
  • 11 acquisitions since 2011
  • Revenue X2 in more than 10 years

Global footprint

  • 24 manufacturing sites in 10 countries
  • 3 continents
  • A broad network of cGMP sites in Europe, the USA and Asia

R&D and Innovation

  • 3,200 employees
  • 300+ scientists, experts and engineers
  • 3 R&D centers (France & USA)

Offering and capabilities

  • 2 main activities: Pharmaceutical synthesis and Specialty ingredients
  • Broad range of technologies spanning all our businesses
  • Ability to manufacture most complex molecules
  • Serving more than 1000 customers in 80 countries
  • 6 targeted end-markets: Pharmaceuticals & Healthcare, Cosmetics & Fragrances, Electronics, Food, Lubricant additives, Homecare

SEQENS : A global and integrated player in Pharmaceutical Synthesis and Specialty Ingredients

carte

2 main activities supported by transverse technologies range, R&D skills and global assets

Pharmaceutical Synthesis

Serving Small-Medtech to Large Pharma
  • CDMO, proprietary APIs, essential drug substances
  • Custom development, contract manufacturing pharmaceutical intermediates
    From complex drug substances to essential molecules

 

Specialty Ingredients

Healthcare, Cosmetics, Electronics and Food 
  • Custom manufacturing and catalog products
  • Complex molecules serving resilient and growing end-markets

Strong R&D capabilities to develop custom-made and differentiating solutions, to speed up our client’s projects by adding value.

3 state-of the-art R&D centers in Europe and the U.S.

Drug Development & Services

Chemistry & Analytics

Biotechnologies

Applicative R&D

A unique range of technologies capable of manufacturing complex molecules, for small and large scale demands
24

Manufacturing sites

3,200

Employees

6

End markets

1000

Customers in more than 80 countries

3

R&D centers

Votre nouveau site dans

days

hours

minutes

seconds